Brenus Pharma
Created in 2019
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
26 4,186Activities
Technologies
Entity types
Location
Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 18
SIREN
802549030Engaged corporates
31
9 13Added in Motherbase
2Â years ago
biotech Value proposition
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide.
We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform.
Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide.
- Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies)
- We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply.
Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development.
We are currently envisaging clinical collaborations.
Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.
oncology, cancer, immune-therapy, innovation, cell therapy, healthtech, biotech, and cancervaccineOriginal language
Next-generation cancer treatment bringing the immune system one step ahead of cancer 🧬🟣
Brenus Pharma is a pioneering clinical stage biotech aiming to prevent cancer recurrence, the main challenge for solid tumors - causing 10M deaths each year worldwide.
We developped a next-generation cancer treatment, thanks to our “off-the-shelf” therapeutic platform.
Our lead candidate is a proteomic-driven immunotherapy targetting colorectal cancer (CRC), the 2nd deadliest cancer worldwide.
- Our allogeneic platform generates therapeutics that efficiently educate the immune system, with more potent, diverse and novel targets than any existing therapies. (Characterized by advanced multiomics technologies)
- We overcome limitations of several technologies such as mRNA vaccines thanks to our enhanced immunogenicity and standardized GMP manufacturing: we keep control of costs and supply.
Awarded “Best Biotech Startup” in 2024 in France, we recently closed a $25M SERIES A to accelerate our clinical development.
We are currently envisaging clinical collaborations.
Brenus Pharma sets a new paradigm in oncology, by giving back to patients the ability to fight against their disease.
Brenus Pharma
https://brenus-pharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Gouvernement | Other | ||
 Groupe Caisse des DĂ©pĂ´ts Finance, Government Administration | Groupe Caisse des DĂ©pĂ´ts Finance, Government Administration | Other | ||
 Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 2 Feb 2025 | | |
 Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Ipsen Pharmaceutical, Pharmaceutical Manufacturing | Other 2 Feb 2025 | | |
 Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Sanofi Pharmaceutical, Pharmaceutical Manufacturing | Other 2 Feb 2025 | | |
 J.P. Morgan Bank | J.P. Morgan Bank | Other 14 Jan 2025 | | |
 | Ministère des Affaires étrangères français | Other 14 Jan 2025 | | |
 Creative Destruction Lab Startup accelerator & VC, Venture Capital and Private Equity Principals | Creative Destruction Lab Startup accelerator & VC, Venture Capital and Private Equity Principals | Other 29 Oct 2024 | | |
 Gustave Roussy Health, Hospitals and Health Care | Gustave Roussy Health, Hospitals and Health Care | Other 9 Oct 2024 | | |
 Pouss@LYS Financial Services | Pouss@LYS Financial Services | Other 7 Dec 2024 | | |